Atsuhito Uneda
Atsuhito Uneda has a total of 129 co-authors. Here are the top co-authors by number of shared publications:
- Yoshihiro Otani
Department of Neurological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
22 shared publications - Kazuhiko Kurozumi
Department of Neurosurgery, Hamamatsu University School of Medicine, Hamamatsu, Shizuoka, Japan
20 shared publications - Tomotsugu Ichikawa
Department of Neurological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan
15 shared publications - Isao Date
Department of Neurological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan
14 shared publications - Tetsuo Oka
Shibaura Institute of Technology, Tokyo, Japan
14 shared publications - Toshihiko Shimizu
Department of Neurosurgery, McGovern Medical School, University of Texas Health Science Center at Houston, Houston, Texas
14 shared publications
Latest Publications
- Open Access
Dual molecular therapy targeting tumor cell heterogeneity improves therapeutic efficacy in glioblastoma
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 1 from Oncolytic Herpes Virus Armed with Vasculostatin in Combination with Bevacizumab Abrogates Glioma Invasion via the CCN1 and AKT Signaling Pathways
Supplementary Figure 1 shows Evaluation of glioma cells infected by oncolytic virus and conditioned medium.
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 1 from Oncolytic Herpes Virus Armed with Vasculostatin in Combination with Bevacizumab Abrogates Glioma Invasion via the CCN1 and AKT Signaling Pathways
Supplementary Figure 1 shows Evaluation of glioma cells infected by oncolytic virus and conditioned medium.
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 3 from δ-Catenin Promotes Bevacizumab-Induced Glioma Invasion
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 3 from δ-Catenin Promotes Bevacizumab-Induced Glioma Invasion
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 1 from δ-Catenin Promotes Bevacizumab-Induced Glioma Invasion
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 1 from δ-Catenin Promotes Bevacizumab-Induced Glioma Invasion
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 4 from δ-Catenin Promotes Bevacizumab-Induced Glioma Invasion
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 4 from δ-Catenin Promotes Bevacizumab-Induced Glioma Invasion
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 3 from δ-Catenin Promotes Bevacizumab-Induced Glioma Invasion
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 3 from δ-Catenin Promotes Bevacizumab-Induced Glioma Invasion
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 2 from δ-Catenin Promotes Bevacizumab-Induced Glioma Invasion
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 2 from δ-Catenin Promotes Bevacizumab-Induced Glioma Invasion